Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 4.5% – What’s Next?

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) traded up 4.5% on Monday . The stock traded as high as $1.16 and last traded at $1.15. 94,159 shares changed hands during trading, a decline of 45% from the average session volume of 169,683 shares. The stock had previously closed at $1.10.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ATNM shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Stephens reissued an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. Finally, StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Actinium Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Price Performance

The company has a market capitalization of $35.88 million, a PE ratio of -0.83 and a beta of 0.13. The firm’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.63.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ATNM. Geode Capital Management LLC increased its holdings in Actinium Pharmaceuticals by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after purchasing an additional 19,843 shares during the period. Northern Trust Corp boosted its stake in Actinium Pharmaceuticals by 4.9% in the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after buying an additional 11,812 shares during the last quarter. Los Angeles Capital Management LLC increased its position in Actinium Pharmaceuticals by 25.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after purchasing an additional 42,770 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Actinium Pharmaceuticals by 49.9% in the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock valued at $240,000 after purchasing an additional 63,400 shares during the period. Finally, Squarepoint Ops LLC grew its holdings in Actinium Pharmaceuticals by 25.4% during the 4th quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock worth $231,000 after acquiring an additional 37,159 shares in the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).